Akari Therapeutics Plc is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapeutics to treat orphan autoimmune and inflammatory diseases. Its lead product candidate, Nomacopan, is a second-generation complement inhibitor. The company was founded on October 7, 2004 and is headquartered in Boston, MA.
Sector:
Health Technology
Industry:
Biotechnology
Employees:
9
Frequently Asked Questions
What is Market Cap of Akari Therapeutics Plc - ADR?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Akari Therapeutics Plc - ADR market cap is $25.77M.
What is the 52-week high for Akari Therapeutics Plc - ADR?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Akari Therapeutics Plc - ADR 52 week high is $3.85 as of September 12, 2025.
What is the 52-week low for Akari Therapeutics Plc - ADR?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Akari Therapeutics Plc - ADR 52 week low is $0.5714 as of September 12, 2025.
What is Akari Therapeutics Plc - ADR stock price today?
Akari Therapeutics Plc - ADR stock price today is $0.77.
What was Akari Therapeutics Plc - ADR stock price yesterday?
Akari Therapeutics Plc - ADR stock price yesterday was $0.79.
What is the PE ratio of Akari Therapeutics Plc - ADR?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Akari Therapeutics Plc - ADR’s P/E ratio is -0.11.
What is the Price-to-Book ratio of Akari Therapeutics Plc - ADR?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Akari Therapeutics Plc - ADR P/B ratio is 1.0063.
What is the 50-day moving average of Akari Therapeutics Plc - ADR?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Akari Therapeutics Plc - ADR 50-day moving average is $0.9983.
How many employess does Akari Therapeutics Plc - ADR has?